Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 101 to 110 of 1509 total matches.
LAAM - Long-Acting Methadone for Treatment of Heroin Addiction
The Medical Letter on Drugs and Therapeutics • Jun 10, 1994 (Issue 924)
(Tegretol), or chronic use of alcohol, could lead to
The Medical Letter, Vol. 36 (Issue 924) June 10, 1994 ...
Methadone, an opioid agonist that can be taken orally, has been used for maintenance treatment for many years in the USA (DM Novick et al, Drug Alcohol Depend, 33:235, 1993). Last year, the US Food and Drug Administration approved the distribution and use of L-alpha-acetyl-methadol (LAAM; ORLAAM - Bio Development Corporation, McLean, VA), a long-acting congener of methadone. LAAM, like methadone, will be available for this indication only through federal and state-regulated treatment programs.
Ketoconazole Shampoo For Dandruff
The Medical Letter on Drugs and Therapeutics • Jul 22, 1994 (Issue 927)
from a
The Medical Letter, Vol. 36 (Issue 927) July 22, 1994, p. 68
Copyright The Medical Letter
UNAUTHORIZED ...
Ketoconazole (Nizoral - Janssen), an imidazole antifungal drug widely used in a tablet formulation for treatment of systemic fungal infections (Medical Letter 36:16, 1994) and as a topical preparation for fungal skin infections, is also available as a shampoo for treatment of seborrheic dandruff. The shampoo is sold only by prescription.
Oral Pilocarpine for Xerostomia
The Medical Letter on Drugs and Therapeutics • Aug 19, 1994 (Issue 929)
, according to Average Wholesale Price listings in Red Book Update, August 1994.
The Medical Letter, Vol. 36 ...
Pilocarpine hydrochloride (Salagen- MGI Pharma), a cholinergic agonist long available in an ophthalmic formulation for treatment of glaucoma (Pilocar, and others), was recently approved by the US Food and Drug Administration (FDA) for oral treatment of radiation-induced xerostomia (dry mouth) in patients with head and neck cancer.
Cysteamine for Cystinosis
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994 (Issue 938)
Letter, Vol. 36 (Issue 938) December 23, 1994 p. 118
Copyright The Medical Letter
UNAUTHORIZED ...
Cysteamine bitartrate (Cystagon - Mylan), an orphan drug, has been approved by the US Food and Drug Administration for oral treatment of nephropathic cystinosis, an autosomal recessive metabolic disorder that affects only a few hundred people in the USA (WA Gahl et al, in The Metabolic Basis of Inherited Disease, 7th ed., CR Scriver et al, eds, New York:McGraw-Hill, 1995, p 3763).
Sevoflurane for General Anesthesia
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995 (Issue 960)
with use of the drug in Japan.
The Medical Letter, Vol. 37 (Issue 960) October 27, 1995, pp. 96-97 ...
Sevoflurane (Ultane - Abbott), a volatile liquid fluorocarbon anesthetic delivered as an inhaled vapor, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia. It is being marketed as a rapidly eliminated anesthetic suitable for inpatient and outpatient surgery.
Dehydroepiandrosterone (DHEA)
The Medical Letter on Drugs and Therapeutics • Oct 11, 1996 (Issue 985)
cancer; the effect of DHEA on the growth
of these tumors is unknown.
The Medical Letter, Vol. 38 (Issue ...
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
Gemcitabine for Treatment of Pancreatic Cancer
The Medical Letter on Drugs and Therapeutics • Nov 08, 1996 (Issue 987)
, and then once weekly
The Medical Letter, Vol. 38 (Issue 987) November 8, 1996, p. 102
Copyright The Medical ...
Gemcitabine (jem site a been) hydrochloride (Gemzar - Lilly), a nucleoside analog, has been approved by the US Food and Drug Administration for intravenous (IV) use in the first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas and in patients with pancreatic cancer previously treated with fluorouracil (Adrucil, and others). No previously available drug has had more than minor activity in treating this disease.
Irinotecan for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 19, 1997 (Issue 992)
January 1997. The costs of administration are additional.
The Medical Letter, Vol. 39 (Issue 992) January ...
Irinotecan hydrochloride (Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs including fluorouracil (5-FU; Adrucil and others).
Intraurethral Alprostadil for Impotence
The Medical Letter on Drugs and Therapeutics • Mar 28, 1997 (Issue 997)
dosage is two pellets in
24 hours.
The Medical Letter, Vol. 39 (Issue 997) March 28, 1997, pp. 32 ...
The prostaglandin alprostadil injected into the corpus cavernosum (Caverject - Upjohn) can produce an erection in some men with erectile dysfunction (Medical Letter, 37:83, 1995). Now a pellet (microsuppository) formulation has become available for intraurethral administration of alprostadil (MUSE [Medicated Urethral System for Erection] - Vivus). It is marketed in a sterile foil pouch containing a pellet 1.4 mm in diameter and 3 or 6 mm long within the stem of a hollow applicator, which is inserted 3 cm deep into the urethra. Pressing a button pushes the pellet into the urethra.
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997 (Issue 1002)
has been a
problem with tacrine, has not been reported with donepezil.
The Medical Letter, Vol. 39 (Issue 1002) June ...
Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993).